Treating the root cause of the pain. Not the symptoms.

Instead of costly procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilizes the disk by transforming it to connective tissue. Unlike any other currently available treatment this has the potential to permanently remove or reduce the pain significantly faster than surgical intervention.

Healthy disc

An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.

DEGENERATED, UNTREATED DISC

When a disc degenerates it becomes less stable and pro-inflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.

Treated disc

By injecting a biologically active substance directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and transform the damaged disc into connective tissue. This helps re-stabilize the intervertebral segment and reduces diffusion of pro-inflammatory substances.

Market outlook: 5 million treatable patients

We are currently taking the next step in our exciting journey towards an injection-based treatment for chronic low back pain. With our STA363 treatment undergoing clinical phase 1b, we are one step closer to market.

Our market

LET’S MEET UP

We are participating in several conferences and industry event every year. Please do not hesitate to contact us to meet up.

Coming events
28 March 2019

Stayble will present clinical phase Ib results at BioSpine 2019 in Rome

Stayble is happy to announce that we will be presenting clinical phase Ib data at the scientific congress BioSpine 2019 in Rome. For further information see: https://www.biospine2019.org

Read more
25 March 2019

Stayble will be attending RESI Europe 2019 in Vienna

Stayble will attend RESI Europe 2019 in Vienna. Our focus at the event funding opportunities regarding our coming phase IIb clinical trial. Do not hesitate to reach out to book…

Read more

Latest news

Stay updated on our development journey

news
28 March 2019

Clinical phase Ib study finalised with very encouraging results

Stayble is very proud to announce that the primary objective of the clinical phase Ib has been completed with very encouraging results. For more information, do not hesitate to contact…

Read more
25 March 2019

Jeff F. Doerzbacher joins Stayble´s scientific advisory board

Stayble is happy to announce that Jeff F. Doerzbacher joins Stayble´s scientific advisory board. He has great experience from developing treatments in the space of degenerative disc disease. Jeff has…

Read more

Get in touch

We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.